Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCO371 in healthy volunteers
NCT02475616Phase 1Terminated
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypoparathyroidism comparing PCO371 with Placebo (2 arms). Primary endpoints: Safety as assessed by adverse events at 22days, Safety as assessed by temperature at 22days and 7 more. Started Jun 2015; status: terminated.
02
Drugs
PCO-371
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT02475616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475616.